ClinicalTrials.gg
RecruitingNCT06293703CLIMBIIUpdated Mar 20, 2026

Effect of Limb Length Ratio on Roux-en-Y Gastric Bypass Outcomes (CLIMB II Study)

An interventional study of Surgery in Morbid Obesity, sponsored by Salvador Navarrete. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Salvador Navarrete · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
262
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 213 studies in Obesity, Morbid with a site in United States — 28 open to participants now, 36 under way, 1 of them phase 3. Obesity, Morbid · United States.

Planned enrollment
14th of 150
262 · median 39
Started
2024
with 11 others
No phase
107 of 213
15 open now
Primary completion
2030-12
later than 32 of 34 live
Registered
203rd of 213
by date

Among the 213 studies in Obesity, Morbid with a site in United States, this one is the 14th largest by planned enrollment of the 150 interventional ones that give a count, is one of 12 that started in 2024, is one of 107 with no phase, reaches primary completion later than 32 of the 34 other live ones, and was the 203rd registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

28 of the 213 studies in Obesity, Morbid with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 213 studies in Obesity, Morbid with a site in United States, or all of them as a file.
02

Study summary

The investigators propose a randomized controlled trial comparing BP and roux limb lengths measuring 30 and 15% respectively of patient's total small bowel length versus current standard practice using fixed lengths. The findings would provide further insight into feasibility of standardizing RYGB limb lengths and optimizing resultant weight loss and metabolic effects. The investigators hypothesize RYGB with ratio-adjusted limb lengths (aRYGB) will result in higher total weight loss and resolution of metabolic syndrome comorbidities, including diabetes, hyperlipidemia, and hypertension compared to standard fixed-length RYGB (sRYGB). The study will also utilize the Short Form Rand 36-Item Health Survey (SF36) to determine differences in postoperative quality of life metrics.

Read the detailed description

This study will be a prospective, randomized controlled trial with a 1:1 recruitment allocation ratio. Patients will be randomized to Standard fixed-length RYGB (sRYGB) or ratio-adjusted limb lengths (aRYGB) once the total small bowel length (TSBL) is fully counted intraoperatively.

sRYGB will serve as the control group which will utilize BP and roux limb lengths of 100cm and 100cm, respectively. For the treatment group, aRYGB will incorporate a BP limb length measuring 30% and a roux limb of 15% of total small bowel length each.

Outcomes to be investigated:

Specific Aim 1: To determine significantly increased Total Weight Loss (TWL) after aRYGB compared to sRYGB in morbidly obese patients Given current understanding that weight loss after RYGB is mediated, at least in part, by a malabsorptive process, the investigators hypothesize that TWL will be greater after aRYGB versus sRYGB. As per standard of care at our institute, routine postoperative follow-up in the multidisciplinary Bariatric clinic will occur every 6 months (± 14 days) or more frequently as clinically indicated for the first two years postoperatively followed by yearly thereafter. Weight will be recorded in kilograms and a BMI will be calculated by the ratio of patient weight in kilograms over patient height in meters squared. Postoperative TWL will then be measured postoperatively at 6, 12, 24, 60 months from surgery.

Specific Aim 2: To compare rates of Diabetes Mellitus (DM) resolution between aRYGB Vs SRYGB by DM subgroup analysis Of the many metabolic changes that occur after bariatric surgery, one of the most salient effects include a rapid and effective resolution of DM. This has been extensively studied in context of various bariatric surgeries, including RYGB by our institution as previously described by the STAMPEDE trial. Significant reduction of HbA1C and improvement in insulin sensitivity was noted as early as six to 12 months postoperatively. As such, this study proposes measurement of the following two metrics at 6, 12, 24, 60 months postoperatively: 1) proportion of subjects achieving HbA1C less than or equal to 6.5%; and, 2) proportion of subjects able to wean and/or discontinue glycemic control medications.

Specific Aim 3: To investigate the relative postoperative efficacy of aRYGB compared to sRYGB on alleviating metabolic syndrome in morbid obesity Metabolic syndrome is a constellation of diagnoses including Hypertension (HTN) and Hyperlipidemia (HLD), which posit significant risk of medical comorbidities such as DM, coronary disease, and strokes. As such, addressing these conditions in morbidly obese patients confers a significant health benefit and decreases overall morbidity. This secondary outcome will be measured by comparing pre- versus postoperative serum lipid levels and proportion of patients requiring less antihypertensives 6, 12, 24, 60 months postoperatively.

Specific Aim 4: To investigate the presence of postoperative vitamin and nutritional deficiencies between the groups.

These secondary outcomes will be addressed comparing the vitamin levels between the groups at 6, 12, 24, 60 months postoperatively.

Additional outcomes proposed include evaluation of postoperative quality of life as captured by the Impact of Weight on Quality of Life-Lite-Clinical Trials (IWQOL-Lite-CT) survey as validated and effectively used in previous investigative bariatric studies. Responses will be tracked and obtained preoperatively and at various postoperative time points including Post-Operative Day (POD) 30 (± 15 days) and POD 365 (± 90 days). The investigators will furthermore track postoperative complications and adverse events, as measured by the Comprehensive Complications Index in addition to instances where additional bariatric surgical interventions are pursued.

03

Conditions studied

  • Morbid Obesity

Browse trials for

Keywords

  • Bariatric surgery
  • Roux-n-Y gastric bypass
  • gastric bypass
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • morbidly obese patients (defined by between 40 and 60).
  • Patient who understands and accepts the need for a long-term follow-up.
  • Patient who agrees to be included in the study

Exclusion criteria

Exclusion Criteria:

  • individuals unable to understand and sign a written consent form
  • patients with history of previous bariatric surgery procedures
  • presence of a severe and evolutive life threatening pathology unrelated to obesity
  • previous gastric or small bowel resection
  • active cancer
  • pregnancy or desired to be pregnant during the study
  • mentally unbalanced patients under supervision or guardianship, patient unable to give consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
262 participants (estimated)

Study arms

  • Experimental
    aRYGB

    BP and roux limb lengths measuring 30% and 15% respectively of patient's total small bowel length.

    Procedure: Surgery

  • Active comparator
    sRYGB

    Standard fixed-length RYGB

    Procedure: Surgery

Interventions

  • ProcedureSurgery

    Biliopancreatic limb and roux limb lengths measuring 30 and 15% respectively of patient's total small bowel length in RYGB

06

What researchers measure

Primary outcomes

  1. To determine change in TWL after aRYGB compared to sRYGB in morbidly obese patients

    Measured in kilograms

    Time frame: 6,12,24 and 60 months from surgery

Secondary outcomes

  1. To compare rates of DM resolution between aRYGB Vs sRYGB by DM subgroup analysis

    Measured by subjects achieving HbA1c less than or equal to 6.5% and subjects able to wean and/or discontinue glycemic control medications

    Time frame: 6,12,24 and 60 months from surgery

  2. To investigate postoperative efficacy rates of aRYGB compared to sRYGB on alleviating metabolic syndrome in morbid obesity

    Measured by a change in serum lipid levels and subjects requiring less antihypertensives

    Time frame: 6,12,24 and 60 months from surgery

  3. To investigate the presence of postoperative vitamin and nutritional deficiencies between the groups.

    Time frame: 6,12,24 and 60 months from surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2030, 82 months after the start.

Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 82 months is above that.

Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2024
First posted
Mar 5, 2024
StartActual
Jan 12, 2024
Primary completionEst.
Dec 11, 2030
CompletionEst.
Dec 11, 2030
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06293703
Lead sponsor
Salvador Navarrete
Responsible party
Salvador Navarrete (Principal Investigator, The Cleveland Clinic) — Sponsor-investigator
First posted
Mar 5, 2024
Start date
Jan 12, 2024
Primary completion
Dec 11, 2030 (estimated)
Completion
Dec 11, 2030 (estimated)
Last update
Mar 20, 2026

Study contacts

Salvador Navarrete, MD
Contact
navarrs@ccf.org
2162199211
Andrew Strong, MD
Contact
stronga3@ccf.org
2162183869
Salvador Navarrete, MD
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion